| 于政一,张诚.组蛋白甲基转移酶在肾透明细胞癌中的相关研究进展[J].安徽医药,2022,26(11):2121-2125. |
| 组蛋白甲基转移酶在肾透明细胞癌中的相关研究进展 |
| Research progress of SETD2 in renal clear cell carcinoma |
| |
| DOI：10.3969/j.issn.1009-6469.2022.11.001 |
| 中文关键词: 肾肿瘤 腺癌，透明细胞 组蛋白甲基转移酶 表观遗传学 协同致死 细胞自噬 |
| 英文关键词: Kidney neoplasms Adenocarcinoma,clear cell Histone methyltransferase Epigenetics Co-lethal Autophagy |
| 基金项目:国家自然科学基金( 81872084) |
|
| 摘要点击次数: 1142 |
| 全文下载次数: 330 |
| 中文摘要: |
| 肾透明细胞癌是我国泌尿系统肿瘤中最为常见的疾病。组蛋白甲基转移酶( SETD2)为哺乳动物表观遗传调控的一个重要基因，对维持生物体内基因组的稳定性具有重要作用。近年来研究表明 SETD2在肾透明细胞癌中存在高频率突变，突变频率仅次于 VHL和 PBRM1，其表达情况与病人的愈后显著相关。该文归纳了 SETD2在肾透明细胞癌中协同致死与细胞自噬方面的最新研究结果，通过分析 SETD2的缺失对转移性肾癌病人耐药性的影响并做出如下综述。 |
| 英文摘要: |
| Kidney cancer is the most common disease of urinary system tumors in our country. Histone methyltransferase (SETD2) isan important gene in mammalian epigenetic regulation and plays an important role in maintaining the stability of the genome in organ.isms. Recent studies have shown that SETD2 has a high frequency of mutations in clear cell renal cell carcinoma, the mutation frequen.cy is second only to VHL and PBRM1, and its expression status is significantly related to the patient's recovery. This article summariz.es the latest research results of SETD2 in synergistic lethality and autophagy in renal clear cell carcinoma, analyzes the effect of the ab.sence of SETD2 on the drug resistance of patients with metastatic renal cell carcinoma, and makes the following review. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
